Autologous hematopoietic stem cell transplantation for adults with acute myeloid leukemia in complete remission: The Edouard Herriot hospital experience

References

• Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremis-sion chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331: 896–903.
   PubMed Web of Science ®Google Scholar
• Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995;332:217–223 .
   PubMed Web of Science ®Google Scholar
• Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone marrow transplan-tation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. Lancet 1998;351:700–708.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997;90:2978–2986.
   PubMed Web of Science ®Google Scholar
• Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: A randomized, controlled trial. Ann Intern Med 1997;126:600— 607.
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Singhal S, et al. Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells. Bone Marrow Transplant 1995;15:652–653.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French—American—British cooperative group. Ann Intern Med 1985;103:620–625.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Chin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187–202.
   Google Scholar
• Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339:1649–1656.
   PubMed Web of Science ®Google Scholar
• Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol 1999;107:69–79.
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Wörmann B, et al. Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML cooperative group. Blood 1999;93: 4116–4124.
   PubMed Web of Science ®Google Scholar
• Bishop JF, Mattews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710–1717.
   PubMed Web of Science ®Google Scholar
• Vey N, Bouabdallah R, Stoppa A, et al. Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from A single institution. Bone Marrow Transplant 2004;33:177–182.
   PubMed Web of Science ®Google Scholar
• Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European group for blood and marrow transplantation study. Blood 1997;90:2931–2938.
   PubMed Web of Science ®Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adults’ acute myeloid leukemia: A southwest oncology group/eastern cooperative oncology group study. Blood 2000;96:4075–4083.
   PubMed Web of Science ®Google Scholar
• Thomas X, Dombret H, Cordonnier C, et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. Leukemia 2000;14:1006–1013.
   PubMed Web of Science ®Google Scholar
• Thomas X, Clapisson G, Chelghoum Y, et al. Prognostic factors influencing autologous peripheral blood stem cell harvest and predicting outcome in adult patients with acute myeloid leukemia. Haema, in press.
   Google Scholar
• Reiffers J, Labopin M, Sanz M, et al. Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: An EBMT retrospective analysis. Bone Marrow Transplant 2000;25:1115–1119.
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Singhal S, et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: Identification of modifiable prognostic factors. Bone Marrow Transplant 1995;16:499–506.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Kantarjian H, Smith TL, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Chin Oncol 1989;7:1071–1080.
   PubMed Web of Science ®Google Scholar
• Estey E, Kornblau S, Pierce S, et al. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acyte myelogenous leukemia. Blood 1996;88:756.
   PubMed Web of Science ®Google Scholar
• Stahnke K, Boos J, Bender-Götze C, et al. Duration of first duration predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 1998;12:1534–1538.
   Google Scholar
• Tomas JF, Gomez-Garcia de Soria V, Lopez-Lorenzo JL, et al. Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission: Importance of duration of first complete remission in final outcome. Bone Marrow Transplant 1996;17:979–984.
   Google Scholar
• Tavernier E, Le QH, Elhamri M, et al. Salvage therapy in refractory acute myeloid leukemia: Prediction of outcome based on analysis of prognostic factors. Leuk Res 2003;27:205–214.
   PubMed Web of Science ®Google Scholar
• Godder K, Eapen M, Laver JH, et al. Autologous hemato-poietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: A prognostic factor analysis. J Clin Oncol 2004;22: 3798–3804.
   PubMed Web of Science ®Google Scholar
• Webb DK, Wheatley K, Harrison G, et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the medical research council (MRC) AML 10 trial. Leukemia 1999;13:25–31.
   PubMed Web of Science ®Google Scholar
• Dusenberry KE, Steinbuch M, McGlave P, et al. Autologous bone marrow transplantation in acute myeloid leukemia: The University of Minnesota experience. Int J Radiat Oncol Biol Phys 1996;36:335–343.
   PubMed Web of Science ®Google Scholar
• Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation/etoposide vs busulfan/cyclophosphamide as pre-paratory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: A south—west oncology group study. Blood 1993;81:2187–2193.
   Google Scholar
• Gorin NC, Labopin M, Fouillard L, et al. Retrospective evaluation od autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the european cooperative group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996;18:111–117.
   Google Scholar
• Reiffers J, Stoppa AM, Attal M, et al. Is there a place for blood stem cell transplantation for the younger adult patient with acute myelogenous leukemia? J Chin Oncol 1994;12: 1100–1101.
   PubMed Web of Science ®Google Scholar
• Sanz MA, de la Rubia J, Sanz GF, et al. Busulfan plus cyclophosphamide followed by autologous blood stem cell transplantation for patients with acute myeloblastic leukemia in first complete remission: A status report from a single institution. J Chin Oncol 1993;11:1661–1667.
   PubMed Web of Science ®Google Scholar
• Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998;92:1073–1090.
   PubMed Web of Science ®Google Scholar
• Reiffers J, Stoppa AM, Attal M, et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: The BGMT 87 study. Leukemia 199610:1874-1882.
   PubMed Web of Science ®Google Scholar